July 1, 2021 In a development having significant ramifications for many biopharma companies, the Federal Circuit has denied Amgen’s petition for rehearing en banc a decision invalidating a genus patent covering its antibody...more
An en banc rehearing petition to the Federal Circuit seeks to breathe life back into the widespread practice of patenting a genus of compounds by claiming their common functional characteristics. This claiming practice was...more
4/30/2021
/ Amgen ,
Appeals ,
Biosimilars ,
Biotechnology ,
Claim Limitations ,
Denial of Certiorari ,
En Banc Review ,
Enablement Inquiries ,
Judgment As A Matter Of Law ,
Patent Litigation ,
Patents ,
Petition For Rehearing ,
Pharmaceutical Patents ,
Section 112